This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Martin, A. Articles by Rowe, P. S. N. Search for Related Content PubMed PubMed Citation Articles by Martin, A. Articles by Rowe, P. S. N.

Degradation of MEPE, DMP1, and Release of SIBLING ASARM-Peptides (Minhibins): ASARM-Peptide(s) Are Directly Responsible for Defective Mineralization in HYP

The Kidney Institute (A.M., V.D., A.-M.H., P.S.N.R.), Kansas University Medical Center, Kansas City, Kansas 66160; The Department of Biochemistry (P.M.S., E.M.L.), The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas 78229; and Department of Pharmaceutical Chemistry and Chemical Petroleum Engineering (J.S.L.), The University of Kansas, Lawrence, Kansas 66044

Address all correspondence and requests for reprints to: Peter S. N. Rowe, Department of Internal Medicine, Division of Nephrology and Hypertension, The Kidney Institute, MS 3018, 3901 Rainbow Boulevard, Kansas City, Kansas 66160. E-mail: prowe{at}kumc.edu.

Mutations in PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) and DMP1 (dentin matrix protein 1) result in X-linked hypophosphatemic rickets (HYP) and autosomal-recessive hypophosphatemic-rickets (ARHR), respectively. Specific binding of PHEX to matrix extracellular phosphoglycoprotein (MEPE) regulates the release of small protease-resistant MEPE peptides [acidic serine- and aspartate-rich MEPE-associated motif (ASARM) peptides]. ASARM peptides are potent inhibitors of mineralization (minhibins) that also occur in DMP1 [MEPE-related small integrin-binding ligand, N-linked glycoprotein (SIBLING) protein]. It is not known whether these peptides are directly responsible for the mineralization defect. We therefore used a bone marrow stromal cell (BMSC) coculture model, ASARM peptides, anti-ASARM antibodies, and a small synthetic PHEX peptide (SPR4; 4.2 kDa) to examine this. Surface plasmon resonance (SPR) and two-dimensional ¹H/¹⁵N nuclear magnetic resonance demonstrated specific binding of SPR4 peptide to ASARM peptide. When cultured individually for 21 d, HYP BMSCs displayed reduced mineralization compared with wild type (WT) (–87%, P < 0.05). When cocultured, both HYP and WT cells failed to mineralize. However, cocultures (HYP and WT) or monocultures of HYP BMSCs treated with SPR4 peptide or anti-ASARM neutralizing antibodies mineralized normally. WT BMSCs treated with ASARM peptide also failed to mineralize properly without SPR4 peptide or anti-ASARM neutralizing antibodies. ASARM peptide treatment decreased PHEX mRNA and protein (–80%, P < 0.05) and SPR4 peptide cotreatment reversed this by binding ASARM peptide. SPR4 peptide also reversed ASARM peptide-mediated changes in expression of key osteoclast and osteoblast differentiation genes. Western blots of HYP calvariae and BMSCs revealed massive degradation of both MEPE and DMP1 protein compared with the WT. We conclude that degradation of MEPE and DMP-1 and release of ASARM peptides are chiefly responsible for the HYP mineralization defect and changes in osteoblast-osteoclast differentiation.

This article has been cited by other articles:

				S. Liu, W. Tang, J. Fang, J. Ren, H. Li, Z. Xiao, and L. D. Quarles Novel Regulators of Fgf23 Expression and Mineralization in Hyp Bone Mol. Endocrinol., September 1, 2009; 23(9): 1505 - 1518. [Abstract] [Full Text] [PDF]

				V. David, A. Martin, A.-M. Hedge, and P. S. N. Rowe Matrix Extracellular Phosphoglycoprotein (MEPE) Is a New Bone Renal Hormone and Vascularization Modulator Endocrinology, September 1, 2009; 150(9): 4012 - 4023. [Abstract] [Full Text] [PDF]

				P. D. Pajevic Regulation of Bone Resorption and Mineral Homeostasis by Osteocytes IBMS BoneKEy, February 1, 2009; 6(2): 63 - 70. [Abstract] [Full Text] [PDF]